U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593976) titled 'Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer' on May 12.
Brief Summary: The GATHER trial aim to evaluate the diagnostic performance of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT in predicting pCR following neoadjuvant chemotherapy. This study is part of the development of new functional, non-invasive approaches with the aim of offering personalized therapeutic approaches.
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
OTHER: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emis...